Innovative solutions to the greatest challenges in pharmaceutical development

11th – 13th March 2019 | Berlin


The perfect mix.
The DDF Summit brings together leading formulation development, drug delivery and device development professionals from both industry and academia to share and discuss their latest work.


Quality content. The agenda is packed with carefully selected talks on topics as diverse as the challenges you face.

Invaluable networking. The DDF community is open, friendly and represents and incredibly valuable network of scientists working at the forefront of their field. There is ample networking time built in to help you make and strengthen connections.

Tailor your experience. 4 parallel streams give you the chance to personalise your agenda and delve deep into the topics pertinent to your challenges. Choose from Small Molecules, Biologics, Technology & Innovation or Device Development.

The right size. This year the DDF Summit will be limited to just 500 people, in order to maintain the quality of the networking and comfort for participants. This means that there will only be 250 delegate tickets available. So, don’t waste time in getting yours.

Key themes for 2019 include:

  • Analytical techniques for biotherapeutics
  • mAb and bispecific formulation development
  • Oral delivery of biologics and other routes
  • Device development and next generation biotherapeutics
  • Nanoparticle formulations
  • Continuous manufacturing
  • Integrating human factors into device development

Have a look at the full agenda here.

Download 2019 Brochure

Speakers

Alan S Harris

Ferring

Senior VP, Global R&D Life Cycle Management

Alessandro Fioni

Chiesi

DMPK Senior Scientist

Anacelia Ríos Quiroz

Roche

Scientist - Group Leader Particle Lab Biologics

Andreas Seidl

Novartis

Head Global Analytical Characterization & Bioanalytics

Anette Müllertz

University of Copenhagen

Professor, Head of Center

April Kent

Amgen

Regulatory Affairs Manager, Devices; Device Lead for AMG 162, IVD Lead for AMG 701 + 596

Beat Steffen

Confinis

Founder and Chief Executive Officer

Beate Bittner

Roche

Senior Portfolio Strategy Director

Ben Van Hove

Janssen

Associate Director Drug Product Development, Oral Solid Dosage Forms

Bjorg K. Hunter

GSK

Regulatory Manager, Devices

Christer Tannergren

AstraZeneca

Associate Principal Scientist in Biopharmaceutics

Christian Lubbert

TU Dortmund University

Postdoc Pharmaceutical Formulations

Corinna Sonderegger

Novartis

Head Portfolio Management Device Development & Commercialization

Cornelus van Nostrum

Utrecht University

Associate Professor

Dr Dimitrios A. Lamprou

Queen’s University Belfast

Reader in Pharmaceutical Engineering

Dr Joshua Boateng

School of Science, University of Greenwich

Reader (Associate Professor)

Dr Rebecca Booth

AstraZeneca

Senior Scientist

Dr. Sebastian Braun

tesa Labtec GmbH

Head of Science & Technology

Dr. Ajay J. Khopade

Sun Pharma Advanced Research Co. Ltd.

Vice President-R&D, Formulation Development (Non-Orals)

Dr. Amrit Paudel

Graz University of Technology, Research Center Pharmaceutical Engineering (RCPE)

Assistant Professor & Principal Scientist

Dr. Carsten Huettermann

DuPont

Senior Application Scientist, Leader Pharma SAFI Innovation EMEA

Dr. Carsten Timpe

Roche

Expert Scientist

Dr. Christian Lotz

Pfanstiehl GMBH

General Manager EMEA

Dr. Federica Mantovani

Elettra

Industrial Liaison

Dr. Gudrun Birk

Merck

Lab Head Controlled Release

Dr. Marco Emgenbroich

LTS Lohmann Therapy Systems

Corporate Senior Director , Head of Pharmaceutical Development I R&D

Dr. Martin Hüelsmeyer

AbbVie

Head of HTS Operations & Analytics NBE Formulation Sciences, Principal Research Scientist

Dr. Matthias G. Wacker

National University of Singapore

Associate Professor

Dr. Matthias Rischer

Losan

Director Drug Delivery & Innovation Projects

Dr. Stefan Bracht

Bayer

Vice President Head of Disruptive Technologies

Dr. Stefan Holzner

Takeda

Senior Director, Head of Device Development

Dr. Yogeshwar Bachhav

AiCuris Anti-infective Cures

Associate Director Pharmaceutical Development

Eleonora Cerasoli

Albumedix

Senior Research Scientist

Feng Zhang

University of Texas at Austin

Assistant Professor

Fred Monsuur

W.R. GRACE & Co.

Excipient Development & TCS Manager

Gabriele Sadowski

TU Dortmund University

Professor for Thermodynamics

Gerhard Wenz

Saarland University

Professor

Graham B Jones

Novartis

Director of Innovation

Héloïse Audat

Sanofi

Head of Late Stage Formulation Development Unit, Biologics

Jacqueline Maximilien

Janssen 

Senior Scientist

James K. Mellman

Novartis

Device Manager

James Meehan

AstraZeneca

Associate Principal Scientist – Human Factors

Jesper Lau

Novo Nordisk

Vice President, Protein and Peptide Chemistry

Johannes Khinast

Research Center Pharmaceutical Engineering

Director

Josef Hartl

Boehringer Ingelheim

Scientist

Kerstin Walke

Boehringer Ingelheim

Head of Pharmaceutical Development Biologicals

Leonie Wagner-Hattler

F. Hoffmann-La Roche

Formulation Scientist

Loredana Casalis

Elettra

Head of Nanoinnovation Laboratory

Louise Place

Cambridge Design Partnership

Head Of Regulatory Affairs and Senior Quality Assurance Consultant

Luigi Boltri

Adare Pharmaceuticals

R&D Director, Innovation and Technology Liaison

Manita Dangol

University College Dublin

Senior Research Fellow

Mara van Haandel

DFE Pharma

Innovation Manager

Marie Wacquet

Sanofi

Drug Product Process Development Unit Manager, Biologics

Matthew Gottschalk

Worrell

Director of Programme Development

Michael Siedler

AbbVie

Head of NBE Formulation Development - NBE Formulation Sciences & Process Development

Michael Hooven

Enable Injections, Inc.

President and CEO

Mostafa Nakach

Sanofi

Head of Pharmaceutical Engineering

Nikki Whitfield

Quotient Sciences

Vice-President, CDMO Services

Patrick Garidel

Boehringer Ingelheim

Associate Director Protein Science

Paul Chamberlain

NDA Advisory Services Limited

Member, NDA Advisory Board

Prof. Dr. Robert Luxenhofer

Wuerzburg University

Chair of Chemical Technology of Materials Synthesis

Professor Ryan F. Donnelly

Queen's University Belfast

Chair in Pharmaceutical Technology

Prof Rainer Jordan

TU Dresden

Professor of Macromolecular Chemistry

Rajeev Gokhale

Roquette

Head Global Pharmaceutical Sciences R&D, Head Asia R&D

Rob Turner

MedPharm

Vice President of Business Development and Innovation

Russ Hornung

W.L. Gore & Associates, Inc.

Business Development – Drug Delivery

Ruzica Kolakovic

Janssen

Senior Scientist, Pharmaceutical Sciences, Drug Product Development

Rémy Vomscheid

Ipsen

Director, Device Development & Technologies

Sabine Eichling

AbbVie

Senior Scientist II, NBE High Throughput and Advanced Formulation Sciences Drug Product Development

Sachin Dubey

Glenmark

Head of Formulation and Analytical Development

Samuel Kyeremateng

Abbvie

NCE Formulation Sciences Senior Scientist

Satya Krishna Kishore Ravuri

Roche

Senior Group Leader, Early-Stage Pharmaceutical and Processing Development

Simon Bjerregaard

Ferring

Senior Research Scientist

Simon Kervyn

Datwyler

Manager Materials Development

Sophie Martin

Sanofi

Process Engineer in Pharmaceutical Development

Stephanie Greco

Sanofi

Head of laboratory in Formulation & Process Development

Stephen Buckley

Novo Nordisk

Head of the Discovery ADME Department in Global Research

Sune Andersen

Janssen

Principal Scientist in Particle Engineering

Sven Stegemann

Lonza

Director, Pharmaceutical Business Development

Thomas Hoeg-Jensen

Novo Nordisk

Scientific Director

Tim Rouse

Chiesi

Senior Scientist

Torsten Kneuss

Bayer

QA Manager Combination Products

Viky Gilles Daniel Verna

Confinis Corporation

Co-Founder and VP

Vipul Yadav

Intract Pharma

Director of R&D

Mafalda Paiva

Hovione

Analytical Scientist, Team Leader Physical and Performance Characterization

X

Download the 2019 Brochure

Download 2019 Brochure